SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

UCM Uscom Limited

Healthcare · Medical Devices · website
$0.01
52wk 0.01 – 0.01
Overall
58.1
Value
71.3
Growth
100.0
Health
54.0
Quality
0.0
Momentum
48.4
Dividend
—
Price
About Uscom Limited

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

Price analytics

Returns

1 day 0.0%
1 week 0.0%
1 month 0.0%
3 months 0.0%
6 months 0.0%
1 year 0.0%
3 years -76.0%

Risk

Volatility (1y ann.) 0.0%
Beta vs ASX 200 0.00
Sharpe (1y) —
VaR 95% (1-day) 0.0%
Max drawdown (1y) 0.0%
Off 1-year high 0.0%

Technicals

RSI(14) 100 OB
vs 50DMA 0.0%
vs 200DMA 0.0%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 71.3
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
95
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 54.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
50
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 48.4
6-month return vs ASX 200
46
Price vs 200-day average
50
Price vs 50-day average
50
Position in 52-week range
—

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$3.12M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
-1.31
EV / EBITDA
-1.10
Price / Book
12.00
ROE
-110.0%
Operating margin
-105.8%
Net margin
-53.6%
Total cash
$1,872
Total debt
$21,093
Current ratio
1.66
Debt / Equity
0.12
Free cash flow
$-1.16M
Avg volume
—
Latest annual results (FY ending 30 Jun 2024)
  • Revenue$3.73M
  • Gross profit$3.12M
  • Operating income-$2.38M
  • Net income-$2.07M
  • Diluted EPS-0.01
  • Free cash flow-$1.22M
  • Net debt-$1.53M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4